-
The first off-the-skin injection PD-L1 was declared public in China for priority review.
Time of Update: 2020-10-03
agreement provides that CorningEry is the sole manufacturer of KN035, responsible for the production and supply of KN03Chinese mainland5; Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".
-
Nature Immunology: Proactively, cancer cells induce immune cells to store lipids in advance to help them metastasy their lungs.
Time of Update: 2020-10-03
study, the authors used a mouse breast cancer model to find that from the pre-transfer stage, the bone marrow-sourced neutral granulocytes accumulated a large amount of lipids after being immersed in the lungs.
-
The departure of Vice President Gilead Kite, the extension of bayer's CEO tenure, the addition of the head of BMS oncology research and development to Blueprint...
Time of Update: 2020-10-03
Peter Emage's role will now be temporarily taken over by Ken Takeshita, Senior Vice President and Global Head of Clinical Development at Kite, and the company will continue to seek a new successor, according to people familiar with the matter.
-
Nature Metabolism: Unhealthy lifestyles are becoming the "pushers" of cancer!
Time of Update: 2020-10-03
From a comprehensive physiological point of view, esograms such as chronic positive energy balance (i.e., obesity espresso) are associated with abnormal mobilization, collection, retention, and function of specific cell types, as well as with molecules that regulate collective disorders in networks, including metabolism, hormone regulation, immune and oxidation balance of host and tissue or tumor micro-environments, and cell and molecular levels.
-
J Clin Oncol: Abemaciclib combined endocrine therapy to treat HR-HER2-lymph node-positive high-risk breast cancer.
Time of Update: 2020-10-03
when used in co-use with ET, Abemaciclib was the first CDK4/6 inhibitor to be shown to significantly improve IDFS in patients with a high risk of early recurrence of HR-HER2-lymph nodes.
-
Lancet: Arteju monoantial is used in complementary chemotherapy for early triple negative breast cancer.
Time of Update: 2020-10-03
study concluded that for early triple-negative breast cancer patients, Artejumodant-albumin-binding yew alcohol-amycin-cyclophosphamide therapy can significantly improve histological pathological response.
-
Professor Yang Yong: Show the dawn of the first-line immunology joint treatment for Reilly Pearl single anti-skin cancer on the urethra.
Time of Update: 2020-10-03
Phase BGB-A317-204 results showed that patients with local late stage or metastatic urethra skin cancer who failed platinum-containing chemotherapy with high expression of PD-L1 monotherapy for Reilly pearl had an objective remission rate of 24.8%, a disease control rate of 38.6%, a medium total survival time of 9.8 months, and good drug safety.
-
Br J Cancer: Nitoju monoantigen anti-combined cisplatin radiotherapy improves prognostication in patients with local advanced head and neck squamous cancer expressed by high HIF1 alpha.
Time of Update: 2020-10-03
the study was designed to analyze the effects and prognostic effects of associated biomarkers in PATIENTs with HPV-negative LA-HNSCC (local late-stage head and neck squamous cell carcinoma).
, the study confirmed that the high expression level of HIF1 alpha indicates that HPV-negative LA-HNSCC patients are less effective at CRT treatment.
-
Lancet Oncol: Navusan anti-new assisted immunochemotherapy greatly improves the prognostics of small cell lung cancer.
Time of Update: 2020-09-30
the trial is an open-label, one-arm Phase 2 trial conducted in 18 hospitals, recruiting untreated, surgically removable IIIA NSCLC patients over the age of 18 for three courses of new complementary treatment: yew alcohol (200 mg/m2), capratin (6 mg/mL.min) and navu monoantigen (360 mg), 1st day of dosing, 1 course/21 days; end point is 24 months of progress-free survival.
-
China's incremental review of cancer innovation drugs approved is based on five major focus points.
Time of Update: 2020-09-30
CDE chemicals clinical director Yang Zhimin gave a speech report data show that in 2020 in the case of the epidemic, the number of new anti-tumor drug approval increased over the same period, from 15 to 19, while the proportion of domestic varieties increased from 26% to 47%.
-
Tonglian officially released colimycin, dedicated to the field of tumor infection precision.
Time of Update: 2020-09-30
On September 17th, Shanghai Tonglian Pharmaceutical Co., Ltd., a scientific and technological innovation biopharmaceutical company focused on building the "G60 Corridor of the Yangtze River Delta", of
-
Preliminary results of a bridding study of Chinese anti-tumor targeting drug Apotony were published.
Time of Update: 2020-09-30
On September 24th, at the 2020 Annual Meeting of the Chinese Clinical Oncology Association (CSCO), Keystone Pharmaceuticals announced the positive results of the China Phase I/II Bridge Study of the anti-tumor drug Apotony tablets.
-
China's cancer innovation drug approval increment, the review based on the five major focus.
Time of Update: 2020-09-30
. CDE chemicals clinical director Yang Zhimin speech report data show that in the case of the epidemic in 2020, the number of new anti-tumor drug approval increased over the same period, from 15 to 19, while the proportion of domestic varieties increased from 26% to 47%.
-
Ovarian cancer relapses within 95% of the year, Fudan tumor Wu Xiaohua team launches "China program"
Time of Update: 2020-09-30
The programme confirmed that patients with relapsed ovarian cancer who received the PARP inhibitor drug Nirapali maintenance had a 68 per cent reduced risk of disease progression or death, and that the patient's medium progression-free survival period reached 18.3 months, well ahead of the control group's 5.4-month data and more than three times longer.
-
80 million reward fund to help cancer research 2020csco public welfare bright strength report card.
Time of Update: 2020-09-30
(Health Times reporter Jing Chao) The 23rd National Conference on Clinical Oncology and the 2020 China Society of Clinical Oncology (CSCO) Annual Meeting recently opened in Beijing! The two-line para
-
To explore new strategies for joint treatment of tumor immunology, an expert seminar was held in Hebei.
Time of Update: 2020-09-30
Professor Wang Zhiyu, Director of Oncology Immunology Department of The Fourth Hospital of Hebei Medical University, pointed out that in order to enrich the treatment of tumors in Hebei and improve the level of cancer treatment, we have been trying to find a variety of combination therapy strategies, such as immuno-combined chemotherapy, immuno-combined radiotherapy, immuno-targeted therapy, double-free combination therapy, drug-carrying vesicles to treat tumor technology.
-
Tumor immunotherapy! Mersadon Keytruda has two new approvals in Japan: esophageal cancer, a 6-week drug administration program!
Time of Update: 2020-09-29
August 25, 2020 // --- Merck and Co recently announced that the anti-PD-1 therapy Keytruda (Corida, generic name: pembrolizumab, Pabliju monotherapy) has received two new approvals from the Japan Medi
-
Cost-benefit analysis of the treatment of glioblastoma by adding tumor electric field to molymine.
Time of Update: 2020-09-29
using sensitivity analysis and self-help methods, the results are found to be relatively reliable and sensitive only to the TTF equipment cost and total survival model.
-
Lung cancer is heavy! AstraZenecom Imfinzi (Infinfan) has been approved by Japan: first-line treatment of extensive stage small cell lung cancer (ES-SCLC)!
Time of Update: 2020-09-29
To date, Imfinzi has been approved in more than 60 countries (including the United States, Japan, China, and the European Union as a whole) for the non-removable, phase III non-small cell lung cancer (NSCLC) patients who have not progressed after receiving platinum-based chemotherapy-based simultaneous radiotherapy.
-
CD39 - The new force of cancer immunotherapy! AbbVie, Covillard Pharmaceuticals, etc. are under development.
Time of Update: 2020-09-29
However, the study found that in the tumor microenvironment, CD39 targeted therapy can enhance anti-tumor immunity through a variety of mechanisms, including reducing adenosine-mediated T-cell immunosuppression, activating inflammatory small bodies in macrophages, affecting NK cell function, inhibiting Treg cell immunosuppression, increasing antigen delivery cell (APC) maturity, and so on (see figure below).
